Fig. 3: T8Ab improves cardiac performance in models of pressure overload and HFpEF.
From: ANTXR1 blockade enhances cardiac function in preclinical models of heart failure
a, Experimental design for ATII/PE prevention model. Vehicle or T8Ab treatments (15 mg kg−1 3× per week, orange arrowheads) began 1 day post-ATII. b, EF%, GLS and ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus velocity (MV E/e′) on day 28. n = 15 mice per group (saline + vehicle and saline + T8Ab) or 19 mice per group (ATII/PE + vehicle and ATII/PE + T8Ab). c, Experimental design for ATII/PE damage reversal model. Vehicle or T8Ab treatments (15 mg kg−1 3× per week, orange arrowheads) began 8 days post-ATII. d, EF%, GLS and MV E/e′ ratios for the study outlined in c. n = 8 (vehicle) or 17 (T8Ab) mice per group. e, Experimental design for HFD/L-NAME model of HFpEF. Vehicle or T8Ab treatments (15 mg kg−1 3× per week, orange arrowheads) began 1 day post-ATII. f, Cardiac function assessment and endurance test results at 35 days post-HFD/L-NAME. n = 15 per group. Results represent mean ± s.e.m. An ordinary one-way ANOVA with Tukey’s post hoc test was used for multiple comparisons (b,d,f). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. The syringe in a, c and e was created in BioRender.
